Phase III study of AZD0780 for elevated LDL cholesterol in adults with atherosclerotic cardiovascular disease or elevated first-event risk

Phase 3, randomised, double-blind trial in hyperlipidemia and atherosclerotic disease comparing LAROPROVSTAT plus background lipid-lowering therapy with Placebo plus background lipid-lowering therapy (2 arms). Primary endpoint: Relative change in LDL-C from baseline to 12 weeks. Planned start Sep 2025; status: authorised.